Minorities With ESRD and Afib Less Likely to Fill Prescriptions for Warfarin Minorities With ESRD and Afib Less Likely to Fill Prescriptions for Warfarin
Minority patients with end-stage renal disease (ESRD) and atrial fibrillation were less likely than whites to fill warfarin prescriptions, even though they were more likely to experience a stroke, researchers say.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 27, 2020 Category: Intensive Care Tags: Nephrology News Source Type: news

J & amp;J and Apple Begin Enrollment for Heartline Study
In the past few years, Apple has greatly increased its presence in healthcare. The Cupertino, CA-based company has received FDA nods for apps associated with its technology and has found itself in several clinical trials. Most recently, the tech giant is seeing some movement in its partnership with Johnson & Johnson’s Janssen Pharmaceutical unit. The companies just opened enrollment for the Heartline Study, which is designed to explore if the Heartline Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection...
Source: MDDI - February 26, 2020 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Cardiovascular Source Type: news

Apple, J & J to study if Apple Watch app leads to lower stroke risk
Johnson& Johnson said on Tuesday it would partner with Apple Inc on a study to use an iPhone app and the Apple Watch to study how earlier detection of atrial fibrillation impacts stroke in people aged 65 or older. (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Apple, J & J open enrollment of Heartline Study to Medicare seniors with iPhones
The study will use the smartphones, Apple Watches and a custom health engagement program to influence stroke risk and atrial fibrillation detection. (Source: mobihealthnews)
Source: mobihealthnews - February 25, 2020 Category: Information Technology Source Type: news

Johnson & Johnson Launches Heartline ™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline™ Study. The study is designed to explore if the Heartline™ Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection of atrial fibrillation (AFib). AFib, a common form of irregular heart rhythm, is a leading cause of stroke in the U.S. To enroll in the Heartline™ Study, individuals must be...
Source: Johnson and Johnson - February 25, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Racial/Ethnic Disparity Seen for Stroke in Dialysis Patients With A-Fib
MONDAY, Feb. 24, 2020 -- Among hemodialysis patients with atrial fibrillation, racial/ethnic disparities in all-cause stroke are partially mediated by lower anticoagulant use, according to a study published online Feb. 20 in the Journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 24, 2020 Category: Pharmaceuticals Source Type: news

Why Human Factors Terminology Needs Updating
Conclusion IEC 62366-1 leaves a chasm between Normal Use and Abnormal Use, so manufacturers might not consider some user actions to be “Use Errors” if these actions do not fit the IEC 62366-1 definition of use. In other words, Use Errors may go undetected, unaddressed, or unmitigated. To protect users and manufacturers, this gap must be closed: IEC 62366-1 should be updated to address user actions that do not fit the current definitions of Normal Use nor Abnormal Use. To mend this gap in IEC 62366-1, we suggest to: Re-define Abnormal Use in terms of abuse. Remove Normal Use. Remove the &...
Source: MDDI - February 19, 2020 Category: Medical Devices Authors: Kaivon Assani Tags: Design Source Type: news

Timing of b-Blocker Reintroduction and AF After Cardiac Surgery Timing of b-Blocker Reintroduction and AF After Cardiac Surgery
Does the timing of timing of beta-blocker reintroduction after cardiac surgery impact its effectiveness on the incidence of postoperative atrial fibrillation?Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2020 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Dronedarone: Implications for Its Use in Atrial Fibrillation Dronedarone: Implications for Its Use in Atrial Fibrillation
This review summarizes real-world evidence on safety and efficacy of dronedarone, focusing on liver safety, mortality risk in patients with paroxysmal/persistent AF, and interactions with DOACs.Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Abbott & #039;s Stellar Week, Cardinal Health & #039;s Supplier Drama, and More
Cardinal Health Severs Ties with Chinese Supplier Cardinal Health nixed its relationship with Suqian, China-based Siyang Holymed after learning that the FDA-authorized supplier had shifted production of Cardinal's surgical gowns to non-approved sites without the proper controlled environments. Unable to ensure the sterility of the gowns produced under those conditions, the company has recalled or initiated a corrective action on 2.9 million procedure packs containing the affected gowns.   Paclitaxel Device Hits a Speedbump in Europe Surmodics is seeking a CE mark for its SurVeil drug-coa...
Source: MDDI - February 8, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

GI Bleeding in OAC-Treated A-Fib Patients Indicates CRC Risk
FRIDAY, Feb. 7, 2020 -- Lower-gastrointestinal (GI) bleeding is associated with high risks for colorectal cancer in patients with atrial fibrillation treated with oral anticoagulation (OAC) therapy, according to a study published online Feb. 6 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 7, 2020 Category: Pharmaceuticals Source Type: news

Bleeding may be a sign of bowel cancer not just a side-effect of blood-thinning drugs
(European Society of Cardiology) Patients who are being treated with blood-thinning drugs for irregular heart beat should always be investigated for bowel cancer if they experience gastrointestinal bleeding, say the authors of a study published in the European Heart Journal. A study of nearly 125,500 Danish atrial fibrillation patients shows those who experienced bleeding were between 11 and 24 times more likely to be diagnosed with bowel cancer, compared to patients who did not have bleeding. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 6, 2020 Category: Cancer & Oncology Source Type: news

Abbott Continues to Show Heart with ‘Breakthrough’ Announcement
Abbott Laboratories continues to extend its list of milestones in the cardiovascular space. The Abbott Park, IL-based company has now won Breakthrough Device Designation from FDA for the in-development Fully Implantable Left Ventricular Assist System (FILVAS). FILVAS builds on the HeartMate 3 Left Ventricular Assist Device (LVAD). The technology was inherited by St. Jude Medical when it was acquired by Abbott. St. Jude inherited Heartmate 3 after it acquiredThoratec for $3.4 billion. Kevin Bourque, Divisional Vice President of Research & Development for Abbott’s Mechanical Circulatory Support portfo...
Source: MDDI - February 5, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news

ICDs Have Come a Long Way in 40 Years
Michel Mirowski and his colleagues gave the field of implantable cardioverter-defibrillators (ICDs) a pretty good start, but what's more impressive is how far the technology has advanced since that first human ICD implant in February 1980. In the past 40 years we've seen ICDs become dramatically smaller, longer lasting, more capable, more personalized, subcutaneous (non-transvenous), and even MRI-firendly. And that's not to mention the advanced data connectivity and monitoring capabilities that the latest technologies offer. So without further ado, let's take a look at the current ICD landscape and the companie...
Source: MDDI - February 4, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Implants Source Type: news

AHA News: Persistent Asthma Linked to Increased Risk for Heart Rhythm Disorder
TUESDAY, Feb. 4, 2020 (American Heart Association News) -- People with persistent asthma could be at 1.5 times higher risk of developing a heart rhythm disorder called atrial fibrillation than those without asthma, new research shows. The study... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 4, 2020 Category: General Medicine Source Type: news

Abbott Wins Approval for CATALYST Trial for At-Risk Stroke Patients
This study is an extremely important step in assessing the Amplatzer Amulet as an effective non-prescription drug alternative for patients with AFib who are at an increased risk for ischemic stroke." In an email sent to MD+DI, Abbott wrote, “We already have an Amulet IDE trial underway that is intended to support our submission for approval in the U.S. for Amplatzer Amulet. The newly announced CATALYST trial will support our submission for an expanded indication for Amulet as a safe and effective alternative to NOAC drugs for patients with atrial fibrillation and at risk of stroke.”...
Source: MDDI - February 3, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news

Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke
- The CATALYST trial will examine Abbott's Amplatzer ™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation (Source: Abbott.com)
Source: Abbott.com - February 3, 2020 Category: Pharmaceuticals Source Type: news

Electrical Cardioversion Effective for Acute A-Fib in Emergency Setting
FRIDAY, Jan. 31, 2020 -- For patients in the emergency department with acute atrial fibrillation, pharmacological cardioversion followed by electrical cardioversion (drug-shock) and electrical cardioversion alone (shock-only) strategies are highly... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2020 Category: Pharmaceuticals Source Type: news

FDA OKs AF, Heart Murmur Algorithms for Eko's Digital Stethoscope FDA OKs AF, Heart Murmur Algorithms for Eko's Digital Stethoscope
The screening algorithms are used with the company's digital stethoscope for early detection of atrial fibrillation and heart murmurs during routine physical exams.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 29, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study
Study (n=121,216) found infection-related AF was associated with increased risk of thromboembolic events compared with infection without AF; 1-year absolute risk thromboembolic events was 7.6% vs. 4.4%, respectively. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 29, 2020 Category: Consumer Health News Source Type: news

Eko ’s New Algorithm Helps Digital Stethoscope Give Insight on Heart Conditions
Eko has won FDA clearance for a suite of algorithms that will allow its digital stethoscope to more accurately screen for heart conditions that include heart murmurs and atrial fibrillation (AFib) during routine physical exams. The San Francisco, CA-based company Eko’s AI identifies heart murmurs with 87% sensitivity and 87% specificity. The company said in comparison, a recent study revealed that using traditional stethoscopes, primary care physicians had a sensitivity of 43% and a specificity of 69% for detecting significant valvular heart disease, which affects more than five million Americans. The AI ...
Source: MDDI - January 29, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Digital Health Source Type: news

FDA clears Berkeley health tech startup's algorithms to detect heart problems
Berkeley health-tech startup Eko was granted FDA clearance today to take its algorithm for detecting atrial fibrillation to the market.   The algorithm, in tandem with a digital stethoscope, is meant to be used to screen for atrial fibrillation and other types of heart disease caused by heart murmurs — a condition that can result in a stroke or heart failure if left untreated. Connor Landgraf, CEO and co-founder of Eko, said it is the first in-office screening algorithm used with a stethoscope… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 28, 2020 Category: Biotechnology Authors: Brian Rinker Source Type: news

FDA clears Berkeley health tech startup's algorithms to detect heart problems
Berkeley health-tech startup Eko was granted FDA clearance today to take its algorithm for detecting atrial fibrillation to the market.   The algorithm, in tandem with a digital stethoscope, is meant to be used to screen for atrial fibrillation and other types of heart disease caused by heart murmurs — a condition that can result in a stroke or heart failure if left untreated. Connor Landgraf, CEO and co-founder of Eko, said it is the first in-office screening algorithm used with a stethoscope… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 28, 2020 Category: Pharmaceuticals Authors: Brian Rinker Source Type: news

Verily Powers up Position in Wearables with New FDA Nod
There are new developments surrounding Verily Life Science’s prescription-only smartwatch. FDA has granted a new clearance for the South San Francisco-based company’s Study Watch to measure irregular heartbeats. The clearance comes one year after Verily received its first 510(k) clearance for ECG for the wrist-worn, sensor-based device. Verily announced in September of 2019 that it collaborated with iRhythm to develop solutions aimed at the Study Watch to improve the screening, diagnosis, and management of patients with atrial fibrillation (AFib). The collaboration brings together iRhyth...
Source: MDDI - January 27, 2020 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Digital Health Source Type: news

Atrial Fibrillation in Athletes: Different but the Same? Atrial Fibrillation in Athletes: Different but the Same?
Studies have shown an increased prevalence of AF among athletes. Are usual AF treatments equally efficacious in athletes and non-athletes? How does continued exercise training influence outcome?Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

One in five over men over 65 at risk of 'invisible' heart fault
Atrial fibrillation is the most common type of irregular heart rhythm, known to affect about 1.3 million in the UK. But experts believe many more people are living with the condition undetected. (Source: the Mail online | Health)
Source: the Mail online | Health - January 25, 2020 Category: Consumer Health News Source Type: news

CardioFocus(R) Names Burke T. Barrett As Chief Executive Officer
MARLBOROUGH, Mass., Jan. 22, 2020 -- (Healthcare Sales & Marketing Network) -- CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the company's Board of Directors has ... Devices, Cardiology, Personnel CardioFocus, atrial fibrillation, HeartLight X3, Endoscopic Ablation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2020 Category: Pharmaceuticals Source Type: news

Medtronic & #039;s Tiny Pacemaker Is Now FDA Approved for AV Block
The device touted as the world's smallest pacemaker is now FDA approved for patients with AV block, a condition in which the electrical signals between the chambers of the heart are impaired. FDA approved the original Micra Transcatheter Pacing System in 2016 for patients with atrial fibrillation or other dangerous arrhythmias such as bradycardia-tachycardia syndrome. The Micra AV is identical in size and shape to the original device, but has several additional internal sensing algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, providin...
Source: MDDI - January 21, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Implants Source Type: news

Wearable May Help Spot Afib, but Doctors Still Required Wearable May Help Spot Afib, but Doctors Still Required
A smartwatch band with integrated electrodes to produce an electrocardiogram (ECG) might be able to help detect atrial fibrillation, but not as well as a traditional ECG machine used in a hospital, a recent study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 19, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Primary Aldosteronism Can Present as Atrial Fibrillation Primary Aldosteronism Can Present as Atrial Fibrillation
Atrial fibrillation can be a presenting sign of primary aldosteronism in patients with hypertension, according to findings from the PAPPHY study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 17, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Smartwatch band may help spot heart problems, but doctors still required
A smartwatch band with integrated electrodes to produce an electrocardiogram (ECG) might be able to help detect atrial fibrillation, but not as well as a traditional ECG machine used in a hospital, a recent study suggests. (Source: Reuters: Health)
Source: Reuters: Health - January 16, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

'Burnout' Could Raise Your Odds for A-fib
Be careful of burnout -- especially after a new study finds it can raise your risk for the dangerous irregular heartbeat known as atrial fibrillation. (Source: WebMD Health)
Source: WebMD Health - January 14, 2020 Category: Consumer Health News Source Type: news

Vital Exhaustion Linked to Increased Risk for Incident A-Fib
TUESDAY, Jan. 14, 2020 -- Vital exhaustion is associated with an increased risk for incident atrial fibrillation, according to a study published online Jan. 13 in the European Journal of Preventive Cardiology. Parveen K. Garg, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2020 Category: Pharmaceuticals Source Type: news

Employees who have 'burn out' at a 20 per cent increased risk of suffering atrial fibrillation
In a study of 11,000 people by the University of Southern California, exhausted and stressed-out workers were at a 20 per cent increased risk of suffering atrial fibrillation later in life. (Source: the Mail online | Health)
Source: the Mail online | Health - January 14, 2020 Category: Consumer Health News Source Type: news

Heart diseases raise risk for kidney failure, study finds
Researchers found that those with a history of heart failure, atrial fibrillation, coronary heart disease and stroke were 10 times more likely to develop kidney failure than those without cardiovascular disease (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 9, 2020 Category: Consumer Health News Source Type: news

AtriCure Completes Patient Enrollment for aMAZE Trial
AtriCure is rolling into the new year with some significant milestones that help reinforce the presence it has built in the cardiovascular space. The company has been at the forefront of the space in the past – by receiving significant investor attention for its work in atrial fibrillation (Afib) and left atrial appendage (LAA) management. Back in 2018, AtriCure was featured prominently in a report detailing the 25 Most Attractive Medtech Companies on the M&A Radar from Needham & Co analyst Mike Matson. Now just a few short days into the new year, the Mason, OH-based company showed why it has alwa...
Source: MDDI - January 7, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

Cutting out alcohol may reduce atrial fibrillation episodes
Eliminating most alcohol consumption dramatically cuts the number of episodes of the potentially deadly heart rhythm disturbance, study says. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - January 7, 2020 Category: Consumer Health News Source Type: news

Take heart: Pitt study reveals how relaxin targets cardiovascular disease
(University of Pittsburgh) As a healthy heart ages, it becomes more susceptible to cardiovascular diseases. Though researchers have discovered that relaxin, an insulin-like hormone, suppresses atrial fibrillation (AF), inflammation, and fibrosis in aged rats, the underlying mechanisms of these benefits are still unknown. In a recent Scientific Reports paper, University of Pittsburgh researchers discuss how relaxin interacts with the body's signaling processes to produce a fundamental mechanism that may have great therapeutic potential. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 7, 2020 Category: International Medicine & Public Health Source Type: news

Withings unveils new watch with ECG, Sp02 capabilities
The new features are designed to help wearers detect the risk of atrial fibrillation and sleep apnea.   (Source: mobihealthnews)
Source: mobihealthnews - January 6, 2020 Category: Information Technology Source Type: news

AHA Names Top Heart Disease, Stroke Research Advances of 2019 AHA Names Top Heart Disease, Stroke Research Advances of 2019
A watch that detects atrial fibrillation, prescription fish oil for CV risk reduction, and the promise of dapagliflozin in HF are among the major advances for 2019, says the American Heart Association.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 2, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Abstinence From Alcohol Cuts Arrhythmia Recurrence in A-Fib
THURSDAY, Jan. 2, 2020 -- In regular drinkers with atrial fibrillation, abstinence from alcohol reduces arrhythmia recurrences, according to a study published in the Jan. 2 issue of the New England Journal of Medicine. Aleksandr Voskoboinik, M.B.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 2, 2020 Category: Pharmaceuticals Source Type: news

One Way to Help Ease A-Fib: Give Up Drinking
THURSDAY, Jan. 2, 2020 -- If you have atrial fibrillation (a-fib) -- a potentially dangerous irregular heart rhythm -- giving up alcohol could ease your symptoms. That's what happened when researchers asked people with a-fib who normally have... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 2, 2020 Category: General Medicine Source Type: news

Cutting out alcohol may reduce atrial fibrillation episodes
(Reuters Health) - For people with atrial fibrillation, abstinence from alcohol may make the heart beat better. (Source: Reuters: Health)
Source: Reuters: Health - January 1, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Perioperative Management of Atrial Fibrillation Perioperative Management of Atrial Fibrillation
What are the challenges physicians face regarding prevention and management of perioperative atrial fibrillation? Review risk factors, outcomes, and clinical strategies in this paper.Anesthesia & Analgesia (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 31, 2019 Category: Surgery Tags: Anesthesiology Journal Article Source Type: news

The Watch Is Smart, but It Can ’t Replace Your Doctor
Apple has been advertising its watch ’s ability to detect atrial fibrillation. The reality doesn’t quite live up to the promise. (Source: NYT Health)
Source: NYT Health - December 26, 2019 Category: Consumer Health News Authors: Aaron E. Carroll Tags: Tests (Medical) Wearable Computing Apple Inc Telemedicine Watches and Clocks Heart Source Type: news

FDA approves first generics of Eliquis
The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Apixaban is also indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (Source: World Pharma News)
Source: World Pharma News - December 26, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
VANCOUVER, Dec. 24, 2019 -- (Healthcare Sales & Marketing Network) - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has received a Complete Response Letter... Biopharmaceuticals, Cardiology, FDA Correvio Pharma, Brinavess, vernakalant, atrial fibrillation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 24, 2019 Category: Pharmaceuticals Source Type: news

FDA Okays First Generics for Eliquis (Apixaban) FDA Okays First Generics for Eliquis (Apixaban)
The FDA has approved two applications for the first generic versions of apixaban to reduce stroke and systemic embolism for patients with atrial fibrillation.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 23, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news

FDA Approves First Generics of Eliquis
December 23, 2019 -- The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 23, 2019 Category: General Medicine Source Type: news